Astex Pharmaceuticals (ASTX) Announces Initiation of the Phase 2 Expansion of the SGI-110 Clinical Trial in MDS and AML Patients
6/22/2012 9:49:18 AM
DUBLIN, Calif., June 22, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated the Phase 2 dose expansion segment of the clinical trial of SGI-110, a novel hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Treatment-naive MDS and elderly AML (=65 years) will be enrolled in the dose expansion.
comments powered by